1 domain / 2 areas / 1 specialization
JLS Fund
Data updated
JLS Fund is a venture capital fund focused on neuroscience and psychedelic medicine. Its website says the firm was founded in 2019 and lists a New York office at 40 Sutton Place, New York, USA.
The fund is active across the psychedelic ecosystem through investments and advisories in companies such as Enthea, Psilera, TRIPP, Gilgamesh, and ProNovo Therapeutics. It also publishes regular industry commentary on psychedelics and neuroscience, which helps position it as a visible specialist investor in the sector.
Investor Context
Venture CapitalInvestment Context
This stakeholder is listed as a Venture Capital Fund within Venture Capital. Its public geography context is global. Public stage signals include Seed, Series A/B, and Growth / Late Stage. Public focus areas include Drug Development.
Public Portfolio Examples
- EntheaFund investment
- PsileraFund investment
JLS Fund presents itself as a venture capital investor in precision neuromedicine, with a visible emphasis on psychedelic medicine and adjacent neuroscience technologies. Its public materials highlight investments and advisories in psychedelic-adjacent and psychedelic-focused companies including Enthea, Psilera, TRIPP, Gilgamesh, and ProNovo Therapeutics, alongside ongoing commentary on developments in psychedelics, brain science, and neuropsychiatry. The fund appears to operate from New York and to support companies moving from early clinical and platform development toward broader therapeutic and commercial applications.
Investor Type
Venture Capital Fund
Geographic Scope
Global
Psychedelic Focus
Explicit Psychedelic Focus
Engagement
Active
Investment Stage Focus
Investment Focus Areas
Portfolio Stakeholders
Recorded Investments
Quick Facts
- Founded
- 2019
- HQ
- 40 Sutton Place, New York, USA, United States
- Website
- Visit